(Q81566308)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

title

Anti-CD20 antibody suppresses anti-HLA antibody formation in a HLA-A2 transgenic mouse model of sensitization (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

8

Stanley C Jordan

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

author name string

Gordon D Wu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Yao He

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Ning-ning Chai

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Mieko Toyoda

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Robert Dunn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Marilyn R Kehry

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

Andrew S Klein

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

publication date

10 June 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

published in

Transplant Immunology

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

volume

19

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

issue

3-4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

page(s)

178-186

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

Consensus opinion from the antibody working group on the diagnosis, reporting, and risk assessment for antibody-mediated rejection and desensitization protocols

9 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Current approaches to treatment of antibody-mediated rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Humoral rejection of organ allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Humoral rejection in kidney transplantation: new concepts in diagnosis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Predicting kidney graft failure by HLA antibodies: a prospective trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Posttransplant therapy using high-dose human immunoglobulin (intravenous gammaglobulin) to control acute humoral rejection in renal and cardiac allograft recipients and potential mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

A comparison of plasmapheresis versus high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Evaluation of intravenous immunoglobulin as an agent to lower allosensitization and improve transplantation in highly sensitized adult patients with end-stage renal disease: report of the NIH IG02 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Management of the sensitized cardiac recipient: the use of plasmapheresis and intravenous immunoglobulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Beneficial effect of plasmapheresis and intravenous immunoglobulin on renal allograft survival of patients with acute humoral rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Isolation and characterization of the B-cell marker CD20.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

The biology of CD20 and its potential as a target for mAb therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

ABO-incompatible kidney transplantation with anti-CD20 monoclonal antibodies, intravenous immunoglobulin and plasmapheresis without splenectomy: a case report

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Rituximab for reduction of anti-HLA antibodies in patients awaiting renal transplantation: 1. Safety, pharmacodynamics, and pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Intravenous gammaglobulin (IVIG): a novel approach to improve transplant rates and outcomes in highly HLA-sensitized patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

First two ABO-incompatible living renal transplantations using splenectomy, rituximab, plasmapheresis and IVIG as a preconditioning regimen: a single center experience in the Balkans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Vascular endothelial cell apoptosis induced by anti-donor non-MHC antibodies: a possible injury pathway contributing to chronic allograft rejection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

CD4+ CD25+ regulatory T cells control the magnitude of T-dependent humoral immune responses to exogenous antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Stat1-dependent synergistic activation of T-bet for IgG2a production during early stage of B cell activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

HLA antibody identification with single antigen beads compared to conventional methods.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

Analysis of HLA class I specific antibodies in patients with failed allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRIM.2008.05.004

10.1016/J.TRIM.2008.05.004

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18595710%20AND%20SRC:MED&resulttype=core&format=json

9 January 2020

1 reference